ArticlePakistan journal of medical sciences2025
Clinical efficacy of Dupilumab in the treatment of moderate to severe Atopic Dermatitis and Type-II Inflammation-Related comorbidities: A real-world study.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Update on biologic and small molecules treatments in pediatric allergic diseases.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate real-world efficacy and safety of dupilumab in children and adults with moderate to severe atopic dermatitis (AD) combined with Type-II inflammatory diseases. Methodology: A retrospective analysis was conducted on pediatric and adult AD patients treated with dupilumab at Renji Hospital (July 2021 to November 2023). Changes in medication scores, symptom severity and quality of life (QoL) assessments at three and six months were compared to baseline. Adverse events were monitored. Results: All 33 patients demonstrated significant improvements in AD medication scores, symptoms and Qol at three/six months vs baseline. Efficacy at three months correlated with six months outcomes. The dupilumab regimen was associated with significantly improved symptoms of Type-II inflammatory comorbidities. Treatment was associated with symptoms that completely disappeared in 18.18% of AR patients and improved in 68.18% of AR cases. Of 11 FA patients, 90.90% reported symptom improvement. The dupilumab regimen led to a 100% and 20% prevalence of symptom improvement in chronic urticaria (CU) and AS patients, respectively, while 80% of AS patients reported complete disappearance of clinical symptoms. Among 15 AC patients, four (26.67%) had symptoms disappeared, seven (46.67%) improved. The dupilumab regimen led to symptom disappearance in one case of a patient with RS. Adverse effects of the treatment were mild. Conclusion: Dupilumab is an effective and safe treatment for moderate-to-severe AD with Type-II inflammatory comorbidities, significantly improving clinical symptoms, reducing concomitant medication needs and enhancing QoL in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.